MichaelMorrisMD

Genitourinary Oncology

Member, Memorial Sloan Kettering Cancer Center Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Morris

Dr. Michael Morris is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. He specializes in genitourinary oncology and his clinical and research focus is on high risk, recurrent, and metastatic prostate cancer, regarding drug, imaging, and biomarker development.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(617) 440-3228

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1994 - 1997
Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1996 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 1
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy Start of enrollment: 2000 Feb 01
Completed
Phase 1
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2001 Jun 01
Completed
Phase 2
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 1, Phase 2
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer Start of enrollment: 2005 Jul 01
Unknown status
Phase 1, Phase 2
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer Start of enrollment: 2003 Feb 01
Recruiting
Not Applicable
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton Start of enrollment: 2008 Aug 01
Completed
Phase 1
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Start of enrollment: 2011 Feb 01
Unknown status
Phase 2
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy Start of enrollment: 2011 Nov 01
Completed
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
Withdrawn
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 3
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Start of enrollment: 2017 Jan 19
Completed
Phase 1
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Recruiting
Phase 3
Safety and Targeting of Anti-hk2 Antibody in mCRPC Start of enrollment: 2019 Sep 18
Terminated
Early Phase 1
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Contact
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer Start of enrollment: 2007 Feb 01
Unknown status
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [Lu]Lu-PSMA...
Andrew J Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi
European Urology. 2024-12-01
1 citations
Standardized template for clinical reporting of PSMA PET/CT scans.
Shadi A Esfahani, Michael J Morris, Oliver Sartor, Mark Frydenberg, Stefano Fanti
European Journal of Nuclear Medicine and Molecular Imaging. 2024-12-01
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
Jeffrey L Jensen, Olivia Bobek, Irenaeus C C Chan, Brian C Miller, David W Hillman
Clinical Cancer Research. 2024-11-01

Lectures

Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspec...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

MSK Research Highlights, October 15, 2024October 16th, 2024
PSA Changes During 177Lu-PSMA-617 Therapy Predict mCRPC OutcomesSeptember 10th, 2024
PET Scans Predict Patient Response to PluvictoAugust 20th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment